Skip to main content
Premium Trial:

Request an Annual Quote

Johannes Fruehauf, Jens Harborth, Greg Weaver

Premium
Cequent Pharmaceuticals said this week that it has named Johannes Fruehauf as its director of preclinical and clinical development.
 
Fruehauf was previously a senior research fellow at Harvard Medical School’s Beth Israel Deaconess Medical Center. He holds an MD from the University of Heidelberg and is a co-developer of Cequent’s core transkingdom RNAi technology.
 
Cequent also said that it has appointed Jens Harborth as its associated director of RNAi research.
 
Harborth was previously a senior scientist at Alnylam Pharmaceuticals. He holds a PhD in biochemistry from Georg-August University.
 

 
Talyst, a pharmacy automation firm, has named Greg Weaver as its CFO.
 

Weaver was previously senior vice president and CFO of Sirna Therapeutics, which was acquired by Merck earlier this year.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.